A team of researchers from the University of Tokyo developed a new technology to monitor blood clotting activity in the actual time without the need for surgical intervention, which paved the way for more accurate and safe treatment for heart patients.
The team relied on a high -speed microscope that works with the technique of “dividing the multiple frequency” (FDM), in addition to artificial intelligence, to accurately analyze the movement of platelets during blood flow, using samples taken from the vein in the arm instead of heart arteries, which makes the examination easier and less dangerous.
In the study, the researchers analyzed blood samples from more than 200 patients with coronary artery disease with varying degrees of severity. Microscopic photos revealed that patients with acute coronary syndrome have more blood sheet accumulations than those with chronic symptoms.
Dr. Kazotoshoshi Hirusi, assistant professor at Tokyo University Hospital and the main promise to study, explained that platelets play a fundamental role in the formation of blood clots, which is one of the decisive factors in heart disease.
The research team indicated that the microscope used takes thousands of images per second for moving blood cells, so that artificial intelligence analyzes them, distinctive between single sheets, their gatherings, and adjacent white cells.
The researchers are similar to this process by monitoring traffic, as every “car” (cell) is monitored on the road.
They explained that artificial intelligence helps in “seeing” patterns that the naked eye can monitor, allowing the discovery of accurate differences in platelet behavior.
The researchers emphasized that this technique may enable doctors to monitor the activity of the platelets in a manner, thus allocating the treatment according to the response of each patient. As some patients may face frequent clots despite the use of anti -platelets, while others may suffer from excessive bleeding due to the excessive response to the drug itself.
“Our technology is a step towards personal medicine in heart disease, as treatments can be modified based on the behavior of the platelets for each individual, instead of adopting a unified approach to all.”
The study was published in Nature Communications.
